- Home
- ANTX vs PIM Comparison
ANTX vs PIM Comparison
Compare ANTX & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTX | PIM |
|---|---|---|
| Founded | 2017 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.9M | 153.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANTX | PIM |
|---|---|---|
| Price | $4.92 | $3.10 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 353.1K | 41.0K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.28% |
| EPS Growth | ★ 32.56 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $63.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $3.07 |
| 52 Week High | $6.91 | $3.50 |
Technical Indicators
Market Signals| Indicator | ANTX | PIM |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 34.59 |
| Support Level | $3.91 | $3.07 |
| Resistance Level | $5.13 | $3.33 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 80.00 | 7.69 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.